Large Molecule Bioanalysis

Large Molecule Bioanalysis for Biologic Drugs, Anti-Drug Antibody (ADA), and Biomarkers

We primarily perform immunological ligand-binding assays (LBA) and enzymatic assays to measure large molecule drugs, ADA, and biomarkers in biological fluids and formulation buffers. Our method validations and sample analyses are compliant with current GLP regulations and FDA guidance on bioanalytical method validation (BMV). While our large molecule bioanalysis services predominantly support GLP preclinical and regulated clinical studies, we also support non-regulated studies, such as exploratory PK and biomarker assessments.

Tell Us About Your Project

What are your specific assay needs? Let’s schedule a conversation to review your questions and requirements with one of our scientists.

Bioanalysis for Large Molecules

BioAgilytix provides the following services for bioanalysis of macromolecules.

  • Most PK sample analyses we conduct use LBA or enzymatic assays that had been validated pursuant to GLP regulations, FDA BMV guidance documents, and current industry standards.
  • We commonly use MSD electrochemiluminescence for LBA because of high sensitivity. ELISA methods are also customary for LBA, while our enzyme methods mostly use fluorescence.
  • We also conduct fit-for-purpose (FFP) “validations,” commonly referred to as a bioanalytical qualification (as distinguished from biomarker qualification for diagnostics).
  • The FFP approach represents a spectrum of assay characterization protocols specifically designed to address the client’s needs, while conserving on expense and time.
  • Either full or FFP validations can be applicable to PK, ADA, and biomarker assays, depending on the needs of the client and the expected level of regulatory review.
  • We can transfer in your ADA assay or make the assay from scratch in our lab. Clients are expected to provide drug reference standard and typically a positive control (PC) antibody. We can subcontract PC antibody production, if necessary, in addition to tending to all other matters required to make an ADA assay for your drug.
  • We evaluate the ADA responses to large and small molecule drugs using a multi-tiered approach as outlined by the 2019 FDA Guidance for Industry: Immunogenicity Testing of Therapeutic Protein Products —Developing and Validating Assays for Anti-Drug Antibody Detection. The multi-tiered approach involves detection of ADA (screening assay), confirmation of ADA specificity by competitive inhibition, and titration of ADA reactivity.
  • Neutralizing ADA (NAb): We have >12 years of experience with NAb, particularly with enzyme therapeutics. Our services can include design and development of a NAb assay in our lab, or transfer-in your method for partial or full validation.
  • Isotypes of ADA: Characterization can include determinations of the predominant ADA isotype(s), such as IgG, IgM, IgA, and IgE; and, if needed, subclasses of IgG.

The most common approach for biomarker analysis is use of commercially available kits. However, we are also experienced with making biomarker assays from “scratch” and with method transfers from clients. We conduct FFP level validations for most biomarker studies and fully GLP compliant validations and sample analyses, when requested by clients for later stage clinical trials. There are two basic formats for biomarker analyses, single analyte (singleplex) and multiplex assays, as described below.

Single analyte commercial kits are very useful but can vary greatly regarding sensitivity, specificity, consistency, and availability. We have experience with a broad array of biomarkers from many kit and reagent vendors and can identify the best option(s) for your biomarker project.
Our primary technology for multiplex biomarkers analysis uses MSD electrochemiluminescence to achieve high sensitivity, but we are also capable of doing multiplex fluorescence. We have substantial experience with custom multiplex designs and can expertly help you design a custom biomarker assay to suit your needs.
Development and validation of bioanalytical methods for the simultaneous quantitation of multiple biomarker peptides or epitope peptides of monoclonal antibodies in serum or plasma matrices.
Model-dependent or model-independent PK/TK analysis of bioanalytical data from discovery, preclinical, GLP toxicology, and clinical studies.
  • Assess the potency of recombinant enzymes/enzyme inhibitors, monitor PD biomarkers, and measure the ADA neutralization activity against recombinant enzymes.
  • Enzyme method validations, like that of LBA PK assay methods, can be fully compliant with current guidance or can be FFP. We model enzyme method validations and sample analyses after current FDA guidance on BMV.

Method Development & Validation for Large Molecule Bioanalysis

We provide full method development and validation for the bioanalysis of large molecules. We primarily perform immunological ligand-binding assays (LBA) and enzymatic assays with method validations and sample analyses that are compliant with current GLP regulations and FDA guidance on bioanalytical method validation (BMV). Our studies predominantly support GLP preclinical and regulated clinical pharmacokinetic (PK), anti-drug antibody (ADA), and biomarker analyses. We also conduct many non-regulated studies, such as for preliminary PK and ADA analyses, as well as exploratory biomarker assessments.

Equipment and Software for Small Molecule Bioanalysis

BioAgilytix occupies 34,000 square feet of office and laboratory space in San Diego, California. Our cutting-edge instrumentation and facilities allow us to increase sample throughput and perform complex separations. Our LC/MS systems and diverse sample preparation technologies allow us to efficiently and accurately analyze large quantities of samples for clients who need high-throughput bioanalysis of clinical study samples.

Featured Case Study

A Brain-derived Neurotropic Factor (BDNF) Immunoassay Able to Quantitate Both Increased and Decreased BDNF Levels over the Course of Disease

Learn how we established a surrogate matrix to quantitate subnormal levels of brain-derived neurotropic factor (BDNF) in sera, as a pharmacodynamic marker of drug treatment in clinical studies, using ligand-binding assay (LBA) technology.

Specimen Collection Kits

Learn how we established a surrogate matrix to quantitate subnormal levels of brain-derived neurotropic factor (BDNF) in sera, as a pharmacodynamic marker of drug treatment in clinical studies, using ligand-binding assay (LBA) technology.

Speak To A Scientist

    I consent to receive communications (which may include, phone, email, social, and re-targeting ads) from BioAgilytix. I understand I may proactively manage my preferences or opt-out of communications with BioAgilytix at any time using the unsubscribe link provided in all of BioAgilytix’s email communications and can learn more by reading the privacy policy.


    Learn why BioAgilytix is a world-leading authority on immunogenicity studies related to ADA, NAb assay development and validation, isotyping, and more.

    Case Studies

    Learn why we’re a trusted partner to 22 of the top 25 global pharma and biotech companies.